Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Down syndrome cell adhesion molecule-like protein 1 (DSCAML1) is a transmembrane protein belonging to the immunoglobulin superfamily and functions as a cell adhesion molecule primarily in the nervous system. DSCAML1 is structurally characterized by ten Ig-like domains and six fibronectin III domains, enabling homophilic cell-cell adhesion critical for neuronal self-avoidance, proper neuronal network formation, cell spacing, synapse specificity, and developmental programmed cell death. The gene is expressed notably in the brain, including the retina, cerebellum, cerebral cortex, dentate gyrus, and hypothalamus, where it regulates development and function of specific neuronal populations. Variants and deficiencies in DSCAML1 are implicated in neurodevelopmental and neuropsychiatric disorders, and it is linked to defective stress axis regulation as well as some vision disorders. There are currently no approved drugs targeting DSCAML1, and it is mainly considered a potential therapeutic or research target in contexts of neurological and stress-related disorders.
Not applicable: No drugs targeting DSCAML1 have defined mechanisms of action
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Down syndrome cell adhesion molecule-like protein 1 (DSCAML1).